Menarini Biotech
Ottavia Pangia possesses extensive experience in biopharmaceutical development, currently serving as a Projects Coordinator in Upstream Process Development at Menarini Biotech since October 2016. Responsibilities include designing experiments and drafting technical reports for the production of monoclonal antibodies and recombinant proteins, utilizing mammalian and microbial cell cultivation in various bioreactors. Previous roles include TD Upstream Development Scientist at GSK, overseeing microbiological activities for the fermentation pilot plant and leading sub-projects for vaccine process characterization, and Cell Line Development Expert at Novartis Vaccines and Diagnostics, focusing on microbiological investigations and fermentation processes for vaccine production. Ottavia's academic background includes a Laurea Specialistica in Biotecnologie Molecolari e Industriali and a Laurea in Biotecnologie Biomolecolari e Industriali from Università degli Studi di Napoli Federico II.
Menarini Biotech
4 followers
Menarini Biotech (“MBH”) is a fast-growing, agile, fully integrated CDMO for biologics located in the greater Rome area, Italy. Established in 2003, Menarini Biotech’s mission is to provide fast and efficient, yet very customer-centric, world-class, high-quality, services for biotech companies from preclinical development to GMP manufacturing (Mammalian and Microbial) up to BSL-2. These include CHO cell line development and analytical development for standard and non-standard mAbs, and new molecular formats, e.g. bispecifics, ADCs, fusion proteins. Our Quality System complies with AIFA/EU GMP requirements.